Kyoto University And U.S. Izumi Bio Collaborate On iPS Research
This article was originally published in PharmAsia News
Executive Summary
Japan induced pluripotent stem cell research center Kyoto University signed a collaboration agreement with U.S. bioventure company iZumi Bio. The two will exchange information on creating human iPS cells using different methods and share analytic results on iPS cell's differentiation capabilities. Funded by major venture capital firms, iZumi obtained Bayer's iPS technology in February. Bayer had previously led Kyoto University in development and submitted the first patent application for iPS in Japan. (Click here for more - Japanese language